Palnon Injection (Palonosetron Hydrochloride)

Adult administration

1. Adults 1) Prevention of nausea and vomiting induced by antineoplastic chemotherapy: Administer palonosetron 0.25 mg once by intravenous injection over at least 30 seconds, 30 minutes before the start of chemotherapy. 2) Prevention of postoperative nausea and vomiting: Administer 0.075 mg once by intravenous injection over at least 10 seconds, immediately before induction of anesthesia. As with other antiemetics, routine administration is not recommended for patients expected to have a low likelihood of postoperative nausea and vomiting. Administration of this drug is recommended for patients in whom postoperative nausea and vomiting must be avoided, even if the likelihood of postoperative nausea and vomiting is low. 3) Treatment of postoperative nausea and vomiting: Administer 0.075 mg once by intravenous injection over at least 10 seconds as soon as nausea and vomiting occur. 3. No dosage adjustment is required for elderly patients or patients with hepatic or renal impairment. There are no clinical data for patients with end-stage renal disease undergoing dialysis.

Child administration

2. Children (2 months and older) 1) Prevention of acute nausea and vomiting induced by antineoplastic chemotherapy: Administer palonosetron 0.02mg/kg (maximum 1.5mg) once by intravenous infusion over at least 15 minutes, 30 minutes before the start of chemotherapy. The safety and efficacy of this drug in neonates have not been established (no data are available). Data on the use of this drug for the prevention of nausea and vomiting induced by antineoplastic chemotherapy in infants (under 24 months) are limited.

This drug should not be used by patients who have allergic reactions to this drug or its components. Patients who have had allergic reactions to similar drugs may also experience allergic reactions when using this drug, so caution is necessary. This drug may slow gut movement; therefore, patients with constipation or symptoms of intestinal obstruction should use it cautiously under medical supervision. Additionally, using this drug with other medications that affect serotonin, a neurotransmitter, may result in a serious side effect known as serotonin syndrome, so patients currently taking such medications need to be particularly careful. When using this drug, side effects such as headaches, constipation, diarrhea, dizziness, fatigue, etc., may occur, so if any unusual symptoms develop, medical consultation should be sought immediately. When engaging in activities requiring alertness such as driving or operating machinery, caution should be exercised as this drug may cause dizziness or drowsiness. Pregnant or breastfeeding women should use this drug only when necessary and must consult a physician before use. The safety and efficacy of this drug in children and the elderly have not been fully established, so consultation with a specialist is required when using it. In the case of overdose, there is no specific antidote, so immediate hospital visit for appropriate treatment is necessary, and caution is required as this drug is not removed by dialysis. This drug should be stored away from direct sunlight and at room temperature, and discoloration or particulate matter must be checked before administration. Remaining medication after use should be disposed of, and while there are relatively few interactions with other medications, it is important to follow a physician's instructions when used in combination with specific drugs.

• Headache
• constipation
• diarrhea
• dizziness
• fatigue
• abdominal pain
• insomnia
• severe constipation
• non-sustained tachycardia
• bradycardia

This drug should be stored at room temperature between 1 to 30 degrees Celsius in a sealed container to prevent air from entering. Additionally, it is important to store it away from direct sunlight to maintain the drug's effectiveness.

Appearance

Colorless transparent liquid in a colorless transparent prefilled syringe

Package unit

1.5mL x 5 prefilled syringes, 5mL x 1 prefilled syringe